Education
About Us
Working with TipRanks
Follow Us
IN8bio (INAB)
NASDAQ:INAB
INAB Stock Chart & Stats
$2.01
-$0.04(-11.59%)
At close: 4:00 PM EST
$2.01
-$0.04(-11.59%)
Day’s Range― - ―
52-Week Range$1.53 - $12.54
Previous CloseN/A
Volume363.43K
Average Volume (3M)74.58K
Market Cap
$7.49M
Enterprise Value-$1.50M
Total Cash (Recent Filing)$10.69M
Total Debt (Recent Filing)$2.96M
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Mar 12, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding4,539,717
10 Day Avg. Volume64,995
30 Day Avg. Volume74,576
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)28.55
Price to Sales (P/S)0.00
P/FCF Ratio-17.04
Enterprise Value/Market Cap-0.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.08
Forecast
1Y Price Target
$4.00Price Target Upside99.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessMultiple doses of INB-200 showed mPFS of 16.1 months, beating historical benchmarks of 6.2 months and 10.3 months in GBM patients with unmethylated or methylated MGMT promoter, respectively.
Preclinical DataIN8bio presented promising preclinical data with their CD19 targeting γδ TCE (INB-619) showing deep B cell depletion in lupus patient blood samples.
Safety ProfileNo new safety concerns were reported. No DLT, ICANS, CRS, or DRI-.
Bears Say
Clinical Trial SuspensionIN8bio suspended enrollment in their clinical trials evaluating INB-200 and '400 in GBM last year, and is actively exploring strategic partnerships and other potential opportunities to further develop this program.
Financial OutlookFollowing the reverse split announced, the share counts were adjusted in the valuation model, resulting in a new price target of $3.
Partnership ExplorationManagement is exploring partnership and collaboration options to further develop the program.
IN8bio News
INAB FAQ
What was IN8bio’s price range in the past 12 months?
IN8bio lowest stock price was $1.53 and its highest was $12.54 in the past 12 months.
What is IN8bio’s market cap?
IN8bio’s market cap is $7.49M.
When is IN8bio’s upcoming earnings report date?
IN8bio’s upcoming earnings report date is Mar 12, 2026 which is in 101 days.
How were IN8bio’s earnings last quarter?
IN8bio released its earnings results on Nov 06, 2025. The company reported -$0.85 earnings per share for the quarter, beating the consensus estimate of -$1.084 by $0.234.
Is IN8bio overvalued?
According to Wall Street analysts IN8bio’s price is currently Undervalued.
Does IN8bio pay dividends?
IN8bio does not currently pay dividends.
What is IN8bio’s EPS estimate?
IN8bio’s EPS estimate is -0.74.
How many shares outstanding does IN8bio have?
IN8bio has 4,539,717 shares outstanding.
What happened to IN8bio’s price movement after its last earnings report?
IN8bio reported an EPS of -$0.85 in its last earnings report, beating expectations of -$1.084. Following the earnings report the stock price went down -6.627%.
Which hedge fund is a major shareholder of IN8bio?
Currently, no hedge funds are holding shares in INAB
Company Description
IN8bio
IN8bio, Inc. (NASDAQ: INAB) is a clinical-stage biotechnology company focused on developing innovative gamma-delta T cell therapies for the treatment of cancer. The company operates in the biotechnology and healthcare sectors, leveraging its proprietary technology platform to create cell-based immunotherapies aimed at targeting both solid tumors and hematologic malignancies. IN8bio's core products are designed to harness the power of the immune system to recognize and attack cancer cells, offering potential therapeutic options for patients with limited treatment alternatives.
INAB Stock 12 Month Forecast
Average Price Target
$4.00
▲(99.00% Upside)
Technical Analysis
Eterna Therapeutics
―
Quoin Pharmaceuticals
―
Xenetic Biosciences
―
VYNE Therapeutics
―
Aprea Therapeutics
―